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1. Introduction
The name of capsaicin is generally used in the medical research, however this material does
not contain a uniform chemical entity. Capsaicinoids covers 5 analogues and 2 homologues
components (Mozsik et al. 2009) (Fig. 1).
It has been established that capsaicinoids interact with capsainin-sensitive afferent nerves
representing a novel regulatory pathway of gastrointestinal funcions (Jancsó et al. 1967,
1968, 1970). Capsaicin-sensitive afferent nerves contain a temperature-gated ion channel
called capsaicin receptor or transient receptor potencil vanilloid 1 (TRPV1) which is ex‐
pressed by a subgroup of primary afferent nociceptive neurons (Szolcsanyi, 2004). The cap‐
saicin receptor has been cloned (Caterina et al., 1997) and has been found to be linked to a
cation channel. It is gated by capsaicin and other capsaicinoids (some vanilloids) by various
treatments including low pH, noxius heat and various pain-producing endogenous an exog‐
enous chemicals. Thus, those sensory nerve endings possessing these ion channels are sus‐
ceptible to being stimulated in the gastric mucosa. Upon stimulation with capsaicin, these
afferent fibers develop four response stages (excitation, sensory-blocking, long-term selec‐
tive neurotoxic impairment, and irreversible cell destruction), depending on the dose and
duration of exposure of the component (Mózsik et al. 2001). A low dose of capsaicin (nano‐
grams to micrograms per kilogram) causes excitation of the nerve endings, and neuropepti‐
des (substance P [SP], calcitonin gene-related peptide [CGRP], and somatostatin) are
released (Holzer et al. 1998, 1999) (Szolcsányi 2004). These mediators can increase mucosal
blood flow by vasodilatation (Holzer et al. 1991), can activate mast cells and immunocells in
© 2013 Czimmer et al.; licensee InTech. This is an open access article distributed under the terms of the
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the mucosa (Stead 1992), and are involved in drug effects (Mózsik et al. 2004, 2005), and so‐
matostatin can elicit systemic anti-inflammatory and analgetic “sensory functions.” The im‐
munodistribution of neuropeptides (SP, VIP, NPY, SOM, GAL, and TH) released from the
sensory neurons and their neuroimmune function are known in H. pylori-positive gastritis
(Sipos et al. 2006). Notwithstanding studies supported that this gastric mucosal protective
mechanism provided by capsaicin-sensitive afferent nerves exists in patients with chronic
gastritis, and its extent does not depend on the presence or absence of H. pylori infection. In
other words, the gastric mucosal protection produced by capsaicin-sensitive afferent nerves
is one of the general defense mechanisms against the different noxious agents that induce
chronic gastritis (Dömötör et al. 2006).
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Figure 1. Names and chemical structures of capsaicin homologs and analogs (with knowledge and allowance of Moz‐
sik et al. 2009).
The vagal nerve has a key-role in the development of gastrointestinal mucosal damage and
prevention (Mozsik et al., 1982). The key-role of vagal nerve has been emphasized domi‐
nantly in the aggressive processes to gastrointestinal (GI) mucosa (such as in peptic ulcer
disease, gastric mucosal damage, etc.) as evidenced from GI investigations in animal models
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and as well as in human clinical practice. The application of capsaicin in the animal experi‐
mentswas used as a specific tool to investigate those primary afferent nociceptive neurones
(Szolcsanyi, 2004; Buck and Burks, 1986; Holzer, 1988; 1991; Szállasi and Blumberg, 1999) in‐
volved in the different physiological, pathological processes.
Szolcsanyi and Bartho (1981) were the first authors, who clearly identified the beneficial and
harmful effect of capsaicin in experimental peptic ulcer in rats, following varying doses of
capsaicin. Later, Holzer undertook extensive investigations on the mode of action of capsai‐
cin on GI functions (Holzer, 1998; 1999; Buck and Burks, 1986; Szállasi and Blumberg, 1999).
We also contributed during the 1980’s to GI capsaicin research from studies in animal mod‐
els (Mózsik et al., 1997c). Recently the new drug, lafutidine, was introduced in the medical
treatment of GI mucosal damage (Ajioka et al., 2000; 2002; Onodera et al., 1995; 1999; Takeu‐
chi, 2006). Lafutidine is a histamine histamine type 2 receptor (H2R) blocking compound
which uniquely has typical capsaicin actions on the target organ.
Capsaicin-sensitive vagal neural afferentation is one of the defensive mechanisms. These
nerves have been shown to play a role in gastric mucosal protection by preventing drug -
induced mucosal injury in animals (Abdel-Salam et al. 1999; Mózsik et al. 1997a; Reinshagen
at al. 1996) and by decreasing the amount of indomethacin (IND)-induced gastric micro‐
bleeding in healthy human subjects (Kang JY et al. 1995; Mózsik et al. 2004b; Mózsik et al.
2005). These mechanisms are well known to be important in protection against gastritis
caused by various harmful effects. The TRVP 1 receptors were also detected in the area post‐
rema and in the nucleus tractus solitary, where the afferent fibres of the vagus nerve taper,
and have key role in regulation of gastric functions i.e. secretion, motiity and protestion
mechanisms.
The vagus nerve consists of 10% efferent nerves, 90% afferents. About 10% of these afferent
nerves are capsaicin-sensitive. The amount of efferent nerves and the capsaicin-sensitive af‐
ferent nerves is roughly equal in the vagus nerve. Capsaicin exposure exerts various re‐
sponses in these afferent nerves depending on dose and exposure duration (excitation,
sensory-blocking, long-term selective neurotoxic impairment and irreversible cell destruc‐
tion) (Vincze et al. 2004). During exposure to small doses of capsaicin (from ng/kg to μg/kg
body weight) neurotransmitters, such as: substance P (SP), calcitonin gene-related peptide
(CGRP) and somatostatin, are released from the nerve endings (Caterina et al. 1997; Mózsik
et al. 2001; Holzer 1998). These mediators are responsible for increasing mucosal blood flow
by vasodilatation (Holzer 1999), activation of mast cells and other immune cells in the muco‐
sa (Szolcsányi 2004; Holzer et al. 1991) and defense of gastrointestinal mucosa.
Capsaicin has been used in human studies, looks to be a suitable treatment tool in several
fields of medicine that can be seen from several running and completes multicentric control‐
led studies worldwide. The United States Pharmacopeia (USP) describes the list of capsai‐
cins and their definition, identification, melting range, and content of capsaicin,
dihydrocapsaicin and other capsaicinoids as follows (USP30-NF25. 2006 Edition, pp.1609):
capsaicin contains not less than 90.0 % and more than 110.0 % of the labelled percentage of
total capsaicinoids. The content of capsaicin is not less than 55 %, and the sum of the con‐
tents of capsaicin and dihydrocapsaicin should not be less than 75 %. The content of other
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capsaicinoids should not be more than 15 %, all calculated on the dried basis. The circum‐
stances of plant cultivation, preparation, storage and other facts are summarized in the drug
master file (DMF). The DMF of capsaicin originated from India was signed by Food and
Drug Administration (FDA) in the United States as existing registration, which allows the
usage of capsaicin as basic source for capsaicin-containing drugs. This type of capsaicinoids
(briefly capsaicin) was used in our previous studies (Mozsik et al. 2009a, 2009b, 2011).
Gastritis is a pathomorphological appearance of inflammation in the gastric mucosa. Acute
and chronic gastritis can be differentiated on the basis of the development and process of the
disease. Chronic gastritis may be caused by different factors such as Helicobacter pylori infec‐
tion, bacterial overgrowt in a hypochlorhydric stomach, autoimmune mechanisms, or chem‐
ical agents such as long-term nonsteroidal anti-inflammatory drug (NSAID) treatment, and
bile reflux (Owen 2003; Appelman 1994, Szabo et al. 2012), for details about mechanisms we
refere to the other chapters of this book. Nowdays, the importance of Helicobacter pylori in‐
fection is increasing as the main causative factor in gastric diseases in humans. This bacteri‐
um is highly prevalent in many countries (Parsonnet 1995) and it increases the risk for
development of gastric and duodenal ulcer disease, gastric cancer, and gastric mucosa-asso‐
ciated lymphoid tissue lymphoma (Janulaityte-Gunther et al. 2005; Mitani et al. 2004; Peng
et al. 1998; Salih et al. 2005; Zhang et al. 2005a, 2005b). Dysfunction of gastrointestinal mu‐
cosal defense mechanisms is also involved in the development of gastric diseases. Capsai‐
cin-sensitive afferent nerves take part in gastric mucosal protection in animals (Mózsik et al.
1997a; Reinshagen et al 1996) and in healthy human subjects (Kang et al. 1995; Mózsik et al.
2004a, 2005a), and the presence of these fibers is proved to play a role in the development of
human gastrointestinal disorders including gastritis, peptic ulcer, polyp without and with
dysplasia, tumor, and inflammatory bowel diseases (Dömötör et al. 2005; Vincze et al. 2004).
The immunodistribution of neuropeptides (SP, VIP, NPY, SOM, GAL, and TH) released
from the sensory neurons and their neuroimmune function are known in H. pylori-positive
gastritis (Sipos et al. 2006).
2. Recent results in human studies
Presentation of capsaicin-sensitive afferentation in the H. pylori positive and H. pylori nega‐
tive chronic gastritis in patients has been studied by Mózsik et al. (2011): The symptoms of
patients sufferring from chronic gastritis with or without H. pylori infection (H. pylori posi‐
tive, n=21, age 39-68 years, screened with [14C] urea breath test, rapid urease test, Warthin-
Starry silver staining and specific histological examinations; H. pylori negative, n=30, age
39-68 years) were nonspecific including gastric dyscomfort sensation, nausea, loss of apetite
and vomiting. The gastric tissue samples from the stomach and antrum were examined by
an independent histopathologist and classified of chronic gastritis according to the Sydney’s
System (Price et al. 1991). The immunohistological studies were carried out on formalin
fixed, parafin embedded tissue samples of gastric mucosa using the peroxidase-labeled pol‐
ymer method (Lab Vision Co., Fremont, USA). SP was detected by the NC1/34HL rat mono‐
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clonal antibody, the TRPV1 receptor and CGRP were labeled using polyclonal rabbit
antisera (all from Alcam Ltd., UK, Cambridge) (Dömötör et al. 2006) (Figs. 2-4).
Figure 2. Immunohistochemical distribution of capsaicin receptor (transitoric receptor potential vanilloid) (TRPV1 in
the gastric mucosa of a healthy (A) and of patient with H. pylori negative (B) and H. pylori positive (C) chronic gastritis.
Arrows indicate the immunosigns in the epithelial layer of the gastric mucosa (original magnification: 100x). From the
ref. (Mózsik et al. 2011), with permission.
Figure 3. Immunoshistochemical distribution of calcitonin gene-related peptide (CGRP) in the gastric mucosa of
healthy subject (A), of patient with H. pylori negative (B) and H. pylori positive (C) chronic gastritis. Arrows demosn‐
trate the immunosign in the epithelial layer of the gastric mucosa (original magnification: 100x). From the ref. (Mózsik
et al. 2011), with permission.
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Figure 4. Immonohsitochemical distribution of subastane P (SP) in gastric mucosa of healthy subject (A), of pateints
with H. pylori negative (B) and positive (C) chronic gastritis. Arrows show the immunosigns in the epithelial layer of the
gastric mucosa (original magnification: 100x). From the Ref. (Mózsik et al 2011), with permission.
Presentation of capsaicin-sensitive afferention of vagal nerve in patients with H. pylori pos‐
itve chronic gastritis of patients, before after after eradication treatment (Mózsik et al
2011):Very recently the same clinical and immunohistochemical examinations were carried
out as those mentioned above in patients with H. pylori positive chronic gastritis before and
after eradication treatment. These observations were carried out in 38 persons, including 20
healthy subjects and 18 patients with H. pylori positive gastritis. The age of persons with his‐
tologically intact gastric mucosa (controls) were between 41 and 67 years (mean=52.2 years).
The age of patients (6 males, 12 females) was 39 to 68 years (mean = 56.4 years).
The time period between the first and control gastroscopy was 6 weeks. The biopsies were
taken from the corpus and antrum of patients with chronic gastritis, before and after eradi‐
dation treatment, and from healthy persons. H. pylori positive patients underwent 7 days
eradication treatment with combination of double dose PPI (pantoprazole 2x40 mg/day),
amoxicillin (1000 mg twice daily) and clarithromycin (500 mg twice daily) according to cur‐
rent European guidelines (Malferteiner et al. 2007). After this one week combination treat‐
ment, patients continued to take normal dose of PPI for another week. The H. pylori infection
was detected before and after by [14 C] urea breath test, rapid urease test, Warthing-Starry
silver staining and specific histological and immmunohistological examinations. The results
of eradication treatment was succesfull in 89%, the gastric histology indicated normal pic‐
ture in 22% of cases, and in 78 per cent patient the mucosa showed moderate gastritis (Lak‐
ner et al. 2011).
Expression of TRPV1 receptor, CGRP and SP in the gastric mucosa of patients with H. pylori
negative and positive chronic gastritis, and before and after successful eradication treatment
(Mózsik et al 2011): The expression of TRPV1 and CGRP increased in the gastric mucosa of
patients with chronic gastritis, however, it was an unexpected that the increase expresson of
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TRPV1 and CGRP did not depend on the presence of H. pylori infection. The changes in ex‐
pression of SP were not significant between these groups of patients.
Another surprising result was obtained in patients with H. pylori positive chronic gastritis
before and after sucessfull eradication treatment. The extent of expression of TRPV1, CGRP
remained at the same level after eradication. No significant changes were obtained in the ex‐
pression of SP in the gastric mucosa in these patients (Fig. 4) (Mózsik et al 2011).
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Figure 5. Chamges in the expression of capsaicin receptor (TRPV1), calcitonin gene-ralated peptide (CGRP) and sub‐
stabtance P (SP) in the human gastric mucosa of healthy voluntaries(histologically intact) (A), H. pylori positive (B), H.
pylori negative (C) and H. pylori positive before (D) and after eradication (pantoprazole 40, amoxicillin 1000 and clari‐
thromycin 500 mg, all two times per day, for seven days) (n=number of patients) (Mózsik et al 2012).
These findings suggest potential role of capsaicin-sensitive afferent vagal nerve in the devel‐
opment of chronic gastritis and the eradication treatment (Mózsik et al 2011): From the ex‐
perimental observations it could be concluded that actions of capsaicin are dose-dependent
(Mozsik et al. 2001, 2005a, 2009b). The types of gastric mucosal injuries could be prevented
by application of small doses (200 to 800μg/person) of capsaicin (Mózsik et al. 2001). Results
of these observations suggest mucosal protecting effect of capsaicin (acting via the stimula‐
tion of capsaicin-sensitive afferent fibres of vagal nerve) in healthy human subjects. These
observations showed that the expression of TRPV1 and CGRP increased siginicantly in infla‐
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mated chronic gastritis, and no significant change was obtained in SP levels. However, these
immunohistochemical results did not differ in patients with H. pylori positive and negative
chronic gastritis. Capsaicin-sensitive afferention did not differ before and after (6 weeks)
successfull eradication treatment in patients with chronic H. pylori positive gastritis (mean‐
while the control biopsy was normal in 22% and in 78% indicated in moderated histological
picture of gastritis) (Lakner et al. 2011).
Explantaion of study group of the for the unchanged immunohistochemical distribution of
TRPV1, CGRP and SP of gastric H. pylori positive chronic gastritis before vs. after eradica‐
tion treatment were as follows (Mozsik et al. 2011):
1. Six week time period (including the eradication treatment) is not enough time for the
complete healing of chronic gastritis.
2. The six-week time period (after eradication treatment) is probably not enought time for
complete histologically recovery of chronic H. pylori positive infection in patients in
term of histology and immunohistology.
3. The H. pylori bacteria as etiological factors might represent only one of the factors caus‐
ing chronic gastritis (in term of histology);
4. The immunohistological distribution (expression rate) of TRPV1, CGRP and SP are in‐
dependent ont the chronic gastritis produced by different physical, chemical, bactero‐
logical or immunological agents. However, the increased expression of TRPV1, CGRP is
involved in the gastric mucosal damage and the normalization of these changes can be
obtained by other way as the classical eradication treatment (Lakner et al. 2011).
Kozlowski et al. (2011) conluded from their study on chronic gastritis: 1. Chronic supeficial
gastritis coexists with significantly higher proliferative activity of gastric mucosal glandular
epithelium, particulary in relation to the prepyloric area and 2. Changes of proliferative ac‐
tivity of gastric mucosal glandular epithelium are independent of age, histotopography and
of H. pylori colonization.
Recent investigations showed that the expression of TRPV1 and CGRP increased significant‐
ly inthe epithelial layer of the gastric mucosa in patients with H. pylori - positive and -nega‐
tive chronic gastritis. The significant etiological role of H. pylori in the development of
chronic gastritis has received great attention in the pertinent literature; for this reason, we
compared the differences in TRPV1,CGRP, and SP expression in H. pylori positive or -nega‐
tive chronic gastritis, suggesting their etiological role in the development of chronic gastritis.
No significant differences were obtained between H. pylori-positive and H. pylori-negative
patients, but values of both groups with chronic gastritis differed significantly from those of
histological intact mucosa of healthy human subjects. Results also indicated that chronic
gastric inflammation is one of the general tissue reactions to different noxious agents, and H.
pylori is only one of these in patients. It must be emphasized that clinicians are able to specif‐
ically demonstrate the presence of H. pylori (by UBT, rapid urease test, and specific histologi‐
cal staining), however, we have no specific methods for well demonstration of other
(suggested) etiological factors.
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In animal experiments, different noxious agents produce the same (or basically similar)
pathological, biochemical (oxygen free radicals), etc., events in the development of gastroin‐
testinal mucosal injury and its prevention (Mózsik et al. 1992). Gastric mucosal damage can
be produced by direct application of ethanol and indomethacin and it can be dose depend‐
ently prevented by the topical application of capsaicin in healthy volunteers (Mózsik et al.,
2005a). Endogenous (increased production of gastric HCl in 4-hr pylorus-ligated rats) and
exogenous (indomethacin given s.c. in a 4-hr experiment, without pylorus ligation) factors
produced changes in functional status and damaged the gastric mucosa in rats. The immu‐
nohistochemical distribution of TRPV1, CGRP, and SP decreased significantly during this
time; the levels of TRPV1 and CGRP returned to those of healthy controls dose dependently
by application of omeprazole and omeprazole-like compounds, and no significant change
was detected in the immunodistribution of SP (Mózsik et al. 1997b). There is no real explan‐
ation for the different expression rates of TRPV1 and mediators released from the sensory
nerves. Similar differences in TRPV1, CGRP, and SP have been observed in many other con‐
ditions (in acute animal models and in patients with chronic gastrointestinal disorders). The
following explanations have been suggested for these differences in expression of TRPV1
and mediators released from sensory nerves (Dömötör et al., 2007): (1) the regulation of SP
differs from that of TRPV1 and CGRP regarding the development of chronic gastritis and (2)
the sensitivity of SP regulation is lower than in the cases of TRPV1 and CGRP. The increased
level of TRPV1 and CGRP is accepted as a signal of an increased defense mechanism pro‐
duced by capsaicin-sensitive afferent nerves in animal experiments (Mózsik et al. 2005a),
and the topical application of capsaicin dose-dependently prevented the mucosal injury pro‐
duced by intragastrically applied ethanol and indomethacin in healthy human subjects
(Mózsik et al. 2005b). These findings suggest that increased expression of TRPV1 and CGRP
is associated with increased gastric mucosal protection. This gastric mucosal protective
mechanism provided by capsaicin-sensitive afferent nerves exists in patients with chronic
gastritis, and its extent does not depend on the presence or absence of H. pylori infection. In
other words, the gastric mucosal protection produced by capsaicin-sensitive afferent nerves
is one of the general defensive mechanisms against the different noxious agents that induce
chronic gastritis.
3. Conclusions
The results of above mentioned animal and human observations indicated clearly the fol‐
lowing considerations:
1. Both acute and chronic gastritis can be induced by different reasons, like chemicals
(drugs) or bacteria (most emphysized one H. Pylori). Both H. pylori positive and negative
gastritis can be acute or chroinic. In case of patients with H.plyori negative gastritis, the
therapeutic approach follows the traditional medical treatment, while H.pylori positive pa‐
tients with gastritis are suggested a rational eradtication treatment only (accepted by many
international consensus meetings).
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Mózsik et al. and Lakner et al. (2011) have demonstrated that while chronic H. pylori pozi‐
tive gastritis heals entirely after a sucessful eradication therapy (which represents an impor‐
tant step to prevent development of gastric cancer), the extents of TRVP1, CGRP remained
in increased level (in comparison to the normal gastric mucosa). This indicates that there is
at least one other important defensive mechanism than antibiotic eradiction treatment, the
capsaicin-sensivite afferention of vagal nerve (results clearly indicated that independent
from H. pylori status and independent from eradication).
Generally it can be concluded that: 1. there can be different mucosal defensive mechanisms
playing key role in treatment of H. plyori positive chronic gastritis: a. eradication treatment
and b. stimulation of capsaicin sensitive afferentation; 2. eradication treatment is independ‐
ent from capsaicin-sensitive afferention (defensive) mechanism; 3. it should be considered to
amend treatment protocols of H. pylori positive chronic gastritis (conventional eradication
therapy and success control) with modification of functional state of capsaicin-sensitive af‐
ferentation. Medical effect of capsaicin for modification of capsacin-sensitive afferent nerves
depends on its dosages, more clinical findngs are needed in the field, that observations are
in progress (Mozsik et al. 2009b, 2011).
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